Objective: The aim of this study was to assess vasomotor and other menopausal symptoms before starting estrogens or placebo, 1 year later, again at trial closure, and after stopping estrogens or placebo. The role of baseline symptoms and age was examined, as was the frequency and determinants of hormone use and symptom management strategies after discontinuing conjugated equine estrogens (CEE) or placebo.
T he randomized, placebo-controlled Women's Health Initiative (WHI) estrogen plus progestin (E + P) trial of postmenopausal women aged 50 to 79 years reported that the health risks of a mean of 5.2 years of combined conjugated equine estrogens (CEE) plus medroxyprogesterone (MPA) clearly outweighed the benefits. 1 Soon after, the Food and Drug Administration advised that menopausal hormone therapy (MHT) not be used to prevent chronic diseases, particularly cardiovascular disease. 2 Subsequently, many women stopped MHT. Reports from two general practices, which included women with a mean age over 60 years, indicated that menopausal symptoms returned in more than 40% of MHT users who stopped long-term MHT, 3, 4 whereas in a third study, 82% reported symptom return. 5 In the WHI E + P trial, hot flashes, night sweats, vaginal dryness, and joint pain/stiffness were significantly reduced 1 year after initiating CEE + MPA compared with placebo 6 ; however, other symptoms, including breast tenderness, vaginal discharge, uterine bleeding, and urinary incontinence, increased. 6Y8 Furthermore, WHI E + P trial participants who had reported moderate or severe menopausal symptoms at baseline were much more likely to report similar symptoms 8 to 12 months after the 5.6-year trial ended compared with participants who were asymptomatic at baseline; however, those who had been assigned to CEE + MPA were more than five times as likely to report symptoms after discontinuing pills compared with those assigned to placebo, regardless of the presence or absence of symptoms at baseline. 8 Combined with the adverse trial findings, 2 the increase in some menopausal symptoms while the woman was taking CEE + MPA and a higher rate of recurrence of bothersome symptoms upon stopping MHT raise new questions about MHT for managing menopausal symptoms.
Most MHT users in the United States are women who have had a hysterectomy and use estrogen without a progestin. 9 The risks and benefits over 7 years of CEE alone (ie, without a progestin) in the WHI trial of 10,379 women who underwent hysterectomy 10 were more balanced compared with those of CEE + MPA. The aforementioned observations indicate the importance of a detailed analysis of menopausal symptoms experienced during and after stopping CEE.
The objectives of the current WHI CEE trial analyses were, first, to compare menopausal symptoms at baseline, 1 year later, and at trial closure (before stopping study pills) in active and placebo groups, by age and presence of symptoms at baseline; second, to assess determinants of moderate/ severe symptoms 6 to 12 months after stopping study pills in participants who continued taking study pills through to study closure; and, finally, to assess the frequency and determinants of MHT use and symptom management strategies after discontinuing CEE or placebo.
METHODS
Details of the WHI CEE trial design, recruitment, randomization, and baseline characteristics of women assigned to CEE or placebo have been described previously. 11<13 Briefly, postmenopausal women aged 50 to 79 years at initial screening were eligible if they had undergone hysterectomy and met specific health criteria. The WHI Estrogen-Only Trial participants were an average of nearly 20 years posthysterectomy at baseline. The number of years since menopause is more difficult to determine because a high proportion (È40%) had also had a bilateral oophorectomy. Approximately 47% of participants had used MHT in the past, including 13% who were taking MHT at initial screening and who were required to stop MHT for at least 3 months before randomization, with the recognition that menopausal symptoms may appear on discontinuation. One third of trial participants reported the presence of one or more moderate to severe menopauseassociated symptoms at baseline. Before randomization, participants completed self-administered questionnaires that included items on menopausal symptoms, the presence of which was neither required nor exclusionary for study entry; however, women were advised not to join if they were experiencing vasomotor symptoms that seriously disrupted their well-being. Participants were randomized to either 0.625 mg/day CEE (Premarin; Wyeth, St Davids, PA) or a matching placebo between 1993 and 1998. An independent data and safety monitoring board assessed health risks and benefits. In March 2004, the National Institutes of Health terminated the intervention phase of the trial and women were instructed to stop taking study pills; however, close-out visits took place during the originally planned period, between October 2004 and March 2005.
To examine symptoms before and after stopping treatment, an BEstrogen-Alone Survey[ was mailed to trial participants who were still taking study pills near the time investigators learned that the trial was being stopped (institutional review board approval of the stopping process was needed). This survey was reviewed and approved by the institutional review boards for the clinical coordinating center (Fred Hutchinson Cancer Research Center) and local clinical centers. The survey was nearly identical to that administered in the WHI E + P trial, with derivation, pretesting, and validity described in Ockene et al, 8 and it had a list of symptoms, the same as that administered at baseline. 14 Participants mailed back the questionnaire. Surveys were considered valid if postmarked before March 1, 2004 , the date of notification to stop taking study pills. Another administration of the Estrogen-Alone Survey, containing the same symptom list given at baseline, at year 1, and in February 2004, before stopping study pills, was completed 7 months later, at the study close-out visit, a mean of 306 days after study pills had been stopped. All surveys used the same symptom list. In addition to symptoms, the survey also asked whether participants were currently taking prescription female hormones, nonprescription hormone-containing treatments, and Bherbal/natural[ hormones, plus questions on other medicines used for managing menopausal symptoms. Only participants who were taking study pills before the trial stopping were eligible to receive the survey, at close-out, after stopping pills.
The Estrogen-Alone Survey, intended for self-administration, provided the following instructions:
Below is a list of symptoms people sometimes have. For each item, mark the one box that best describes how bothersome the symptom was for you during the past 4 weeks. Be sure and mark one box on each line. If you do not have the problem, please mark the box under BSymptom did not occur.[ If you have the symptom, use the following key to indicate how bothersome it is: Mild = symptom does not interfere with usual activities. Moderate = symptom interferes somewhat with usual activities. Severe = symptom is so bothersome that usual activities cannot be performed.
Statistical approach and analysis
Analysis of WHI CEE clinical trial data (n = 10,739; yellow boxes in Fig. 1 ) focused on the incidence of symptoms at year 1. Comparisons of active to placebo, stratified by the presence or absence of baseline symptoms, are presented as relative risks (RRs) and 95% CIs along with P values for the main effect of CEE on symptom incidence and P values for the interaction between CEE and the presence or absence of baseline symptoms (P-int). Estimated RRs (95% CIs) and P values were obtained from generalized linear models. Further analyses of these RRs as modified by age were conducted.
A similar analysis of the prestopping and poststopping incidence data from the Estrogen-Alone Survey was also conducted; comparisons of incidence before stopping were stratified by baseline symptoms, and comparison of incidence after stopping was stratified by baseline symptoms and separately by symptoms before stopping. This analysis included the WHI CEE trial participants (n = 3,496; red boxes in Fig. 1 ) who were taking study pills at trial closure and had completed both Estrogen-Alone Surveys before stopping study pills (green boxes in Fig. 1 ) and after stopping study pills (blue boxes in Fig. 1 ). This portion of the study is composed of a unique subsample of the randomized participants and may be considered observational. To examine selection bias and to better understand the limitations of the analysis, the demographic and health parameters of the subset of respondents were compared with the whole CEE trial cohort.
The analyses differ from those described in the preset protocol for the hormone therapy (HT) clinical trial as both on-trial and posttrial data are considered. Estimated RRs (95% CIs) and P values were obtained from generalized linear models that were adjusted for potential confounders. For this subsample, age, years since menopause, and history of HT use were significantly associated with treatment assignment (P G 0.05) and identified as potential confounders.
For all testing, P values were two sided, and P e 0.05 was designated as significant. All analyses were conducted with SAS version 9.0 (SAS Institute Inc., Cary, NC). Figure 1 depicts eligibility and actual participation at the prestopping and poststopping data collection points for the subset of participants who were still taking study pills in March 2004, when study pill administration was halted (n = 3496). Table 1 shows the proportion of women by age who reported specific symptoms at baseline, that is, before study treatment began, for all women who were randomized. More than 20% of women in age groups 50 to 54 and 55 to 59 years reported vasomotor symptoms (hot flashes or night sweats), whereas a much lower proportion of women aged 60 to 69 years and an even lower percentage of women aged 70 to 79 years reported these symptoms. Vaginal dryness and breast tenderness were also reported by a smaller proportion of women from youngest to oldest age groups, whereas joint pain was reported by about 30% of women of all ages. Moderate or severe sleep disturbance at baseline was also reported by about a third of women, with slightly declining proportions with age.
RESULTS

Randomized trial analyses
Baseline to year 1 treatment effects Table 2 shows the proportion of women reporting specific symptoms at year 1 postrandomization by the presence of relevant symptoms at baseline and the corresponding RRs for CEE versus placebo, as well as whether the presence of the symptom at baseline interacted with treatment assignment to affect year 1 symptoms (shown as P-int). For women either with or without the symptoms at baseline, CEE had a greater effect in reducing or preventing hot flashes, night sweats, and vaginal dryness than placebo did (each P G 0.001). There was a marginal effect of CEE on joint pain (P G 0.04), no effect of CEE or placebo on mood swings and sleep disturbance (data not shown), and no differences comparing women with or without these symptoms at baseline. In contrast, CEE increased (P G 0.001) the risk of breast tenderness more than placebo did in groups both reporting and not reporting the symptom at baseline. In absolute terms, breast tenderness occurred in about 3% of the population. This adverse effect was significantly (P G 0.001) higher among women who did not have breast tenderness at baseline, but the differential effect was smaller than for hot flashes and night sweats. CEE was not effective in reducing or preventing reported mood swings. Risk for breast tenderness increased with age (P-int G 0.001): RR (95% CI), 1.45 (1.04-2.10) for women aged 50 to 59 years, 2.59 (1.99-3.36) for women aged 60 to 69 years, and 4.35 (2.91-6.51) for women aged 70 to 79 years. No age-related trends were found for the other symptoms (P-int 9 0.25).
Subsample (observational) analyses: participants taking assigned study pills at trial end and completing prestopping and poststopping surveys
The subsample of participants who were still taking the assigned study pills at the time the trial was stopped and who completed prestopping and poststopping Estrogen-Alone Surveys differed somewhat in baseline vasomotor symptoms At the time the intervention was stopped (mean, 7.1 y; range, 5.7-10.7 y from baseline), 46% of the CEE trial cohort was still taking study pills, and 71% of these women completed both prestopping and poststopping symptom questionnaires ( Fig. 1) . A mean of 306 T 55 days elapsed between the administration of prestopping and poststopping surveys. Women who were eligible (were not deceased, stopped, or lost to follow-up and were still taking study pills) and completed all surveys. e Proportion of women reporting symptoms before stopping study pills. f Total number of participants; denominator of (5). and years since menopause (18.5 T 9.7 y vs 18.9 T 9.6 y) were similar between groups.
The proportion of women reporting hot flashes and night sweats had declined by trial closure (prestopping) compared with baseline to about 11%, independent of age, and both of these symptoms were significantly reduced in the CEE treatment group. The proportion of women reporting breast tenderness was significantly higher with CEE than with (Table 3 ) but, again, was an infrequent symptom in absolute terms.
Among women still taking study pills, women taking CEE who were not experiencing hot flashes at baseline were more likely to report moderate to severe hot flashes after stopping pills than were women taking placebo (Table 4 ). A similar pattern was seen for night sweats although the interaction was not statistically significant. Women taking CEE were also more likely (increase of about 8%) to report joint pain after stopping regardless of whether the symptom was present or absent before stopping.
Among women still taking study pills, those assigned to CEE who had not reported hot flashes or night sweats before stopping were more likely to report hot flashes and night sweats after stopping compared with placebo ( Table 5 ). It should be noted that in absolute numbers, about 3% of women reported these symptoms. A similar pattern was seen for breast tenderness, although the interaction was not statistically significant.
Older women were at higher risk for joint pain after stopping CEE compared with placebo pills (P-int = 0.04). The same trend existed for both previously asymptomatic and symptomatic women, with the following RR (95% CI): for asymptomatic women, 0.98 (0.51-1.89) for those aged 50 to 59 years, 1.23 (0.90-1.67) for those aged 60 to 69 years, and 1.30 (0.99-1.71) for those aged 70 to 79 years; for symptomatic women, 0.81 (0.60-1.08), 1.09 (0.93-1.28), and 1.26 (1.08-1.48) for women in the respective age groups.
Lifestyle strategies
After the trial ended, 4.5% of women reported taking prescription hormones. Only 1.8% of women who had been taking placebo used prescription hormones after trial closure, compared with 7.2% of those who had been taking CEE. Most (89%) women did not start any type of HT, either prescribed or over-the-counter, after the trial ended (Table 6 ). Women who began using HT (nonprescription and/or prescription) after stopping, when compared with women who did not begin using HT after stopping, were more likely to have been randomized to active intervention (P G 0.001), had experienced baseline vasomotor symptoms (P G 0.001), and reported current HT use at baseline (P G 0.001).
The most frequently cited reason for starting treatment after the trial was to Bdeal with symptoms[ (reported by 61% of the 158 women who began taking hormones), with Badvice from healthcare provider[ cited by 42% and Bto feel better[ cited by 40% in this same group. Prevention of osteoporosis was cited by 18%, whereas Bother disease[ prevention was cited by 6%.
DISCUSSION
The WHI Estrogen-Only Trial participants were nearly 20 years posthysterectomy at baseline, and a large proportion (È40%) had had a bilateral oophorectomy; furthermore, about 13% had been taking MHT until about 3 months before being randomized into the trial. Therefore, the timing of menopause was difficult to determine. At study baseline, approximately 12.5% of women reported moderate to severe hot flashes and night sweats, 10.7% reported vaginal dryness, and 3.5% reported breast tenderness, with the proportion decreasing by baseline age for most symptoms, except for joint pain/stiffness, which nearly one third of women reported in all age groups. One year after randomization to CEE or placebo, several symptoms, that is, hot flashes, night sweats, and vaginal dryness, were significantly improved by CEE, whereas breast tenderness/sensitivity was significantly worsened, compared with placebo. CEE did not significantly affect mood, joint pain, or sleep (data not shown) 1 year after baseline.
In the women who were still taking study pills at trial closure, that is, approximately 46% of the cohort, symptoms were assessed again before breaking the treatment blind. At this time point, 7.1 years after baseline, CEE continued to be associated with fewer hot flashes (but not reduced night sweats) and with increased breast tenderness compared with placebo. We assessed symptoms in this subset a mean of 306 T 55 days after the study pills had been stopped and participants had learned of their treatment assignment. At this point, symptoms were reported by significantly more women who reported them at baseline and by more women who had been assigned to CEE than to placebo. Furthermore, among women who did not have moderate or severe vasomotor symptoms at baseline, those assigned to CEE were significantly more likely to report symptoms after stopping study pills than were those assigned to placebo (7.2% and 1.5%, respectively; RR, 5.01).
Observational studies and clinical experience have shown that vasomotor symptoms occur after stopping menopausal hormone treatment 3 even if treatment is long-term and the withdrawal is gradual. 15 In the WHI trial of combined CEE + MPA, discontinuation of active treatment was shown to increase the risk of symptoms (vasomotor and joint stiffness) by more than four times in women with prior symptoms and by seven times in those without prior symptoms, compared with placebo. Thus, it seems that CEE, with or without progestin, may promote vasomotor symptoms when treatment is withdrawn, regardless of whether symptoms were present at baseline.
In addition to vasomotor symptoms, joint pain/stiffness had been 5% lower during treatment (year 1) with CEE than with placebo, but this suppression was reversed after stopping study pills. Significantly more (5.4%) women in the CEE group compared with the placebo group reported joint pain/stiffness after stopping. The incidence of breast tenderness/sensitivity was marginally higher only after discontinuation of active treatment compared with placebo (2.5% and 0.9%, respectively), indicating a rapid decline in estrogen-induced breast tenderness upon discontinuation of therapy.
Only 4.5% of women reported taking prescription hormones on the posttrial questionnaire (about 10 mo after the end of the trial). This is in contrast to the report from a Kaiser Foundation observational study in which about 26% of women restarted within a year after stopping. 16 Reasons for stopping were not assessed, but the development of either troublesome vasomotor symptoms or other troublesome symptoms was each independently associated with unsuccessful stopping. Most studies of stopping MHT examined women who stopped because of the WHI results, and among these, 18% to 28% restarted. 5, 17 There are a number of factors that would explain a higher restarting rate in women in other studies who had stopped HT compared with our research cohort, including differences in age, symptom severity, personal inclination to choose hormones, treatment flexibility, nonplacebo nature of the treatment, and provider influence.
The WHI is the largest study to look at symptoms after stopping hormones. Because this study was conducted among women specifically selected to participate in a clinical trial, the generalizability of the findings to women of this age in the population is uncertain. Furthermore, several of the findings are limited to the approximately 46% of participants in the active treatment and placebo groups still adherent to their assigned study pills by the end of the trial. Some women who stopped study pills early initiated hormones through their private healthcare provider (5.7% in the CEE group and 9.1% in the placebo group). Another limitation is that we tested only one hormone formulation and only one mode of delivery and began with women who indicated that they could tolerate symptoms without hormone treatment. Therefore, we do not know how well the findings generalize beyond the treatments and population studied; older women may regard symptoms differently than would younger women who had a recent hysterectomy. Knowledge of treatment assignment (ie, participants were no longer blinded) may have influenced responses in that administration of the poststopping survey was not blinded. In addition, the cohort of participants who continued to take study pills until the end of the trial differed in several characteristics documented at baseline from those who stopped early. It is important, however, that there were no significant differences in baseline vasomotor symptoms between respondents and nonrespondents to the surveys.
Both WHI hormone trials demonstrate that for many women, menopause-related vasomotor symptoms will abate over time without any intervention. Our findings are also consistent with studies showing that for some women, symptoms and conditions associated with the menopausal transition may continue for many years and may reappear, or appear as new symptoms, upon discontinuation of HT. 18 Another study has shown that moderate to severe vasomotor symptoms, sleep difficulties, depression, and pain appear at the menopausal transition in less than half of women studied. 19 In that study, hot flashes and night sweats were more common 3 years after menopause than in perimenopause or 1 year after menopause. Gold et al 20 also found that symptoms were reported nearly as often in postmenopause as in perimenopause.
We found that HT may postpone symptoms for many years in some women who underwent hysterectomy. In absolute terms, among women with vasomotor symptoms at baseline, we found that only 10.1% had hot flashes and 15.7% had night sweats after an average of 7.4 years on CEE. However, among these same women with vasomotor symptoms at baseline, the percentage of hot flashes and night sweats increased from these prestopping rates to 28.6% and 31.3%, respectively, after stopping study hormones at a mean age of 73 years. Thus, it seemed that for some symptomatic women, CEE like CEE + MPA therapy relieved several symptoms (except for breast tenderness, which increased) but did not permanently eliminate them. This recurrence phenomenon may make it difficult for some symptomatic women to follow the consensus recommendation to use MHT for a short period of time. One position statement noted that management of severe symptoms is a primary basis for extended use of HT Bfor the woman for whom, in her own opinion, the benefits of menopause symptom relief outweigh risks, notably after an attempt to stop HT.[ 21
CONCLUSIONS
These findings support current recommendations not to initiate MHT for women without symptoms, except as a treatment for the prevention of osteoporosis. For clinicians advising women who are experiencing symptoms, this study confirms the beneficial effects of MHT on symptoms while receiving treatment and offers additional data about the possibility of experiencing symptoms after stopping, even after long-term therapy. This information is particularly relevant, given current recommendations to prescribe MHT in the lowest effective dose and for the shortest duration consistent with individual treatment goals and risks. Future research may be directed to continuing to characterize the intensity and duration of recurrent menopausal symptoms, the women at highest risk for recurrence, and the physiological mechanisms that are involved.
